reviewPharmacological ResearchDec 17, 2019Closed access

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update

RRRobert Roskoski

Blue Ridge Research and Consulting (United States)

PubMed
Indexed incrossrefdoajpubmed

Abstract

No abstract available for this paper.

Citation impact

581
total citations
FWCI
59.06
Percentile
100%
References
105
Citations per year

Authors

1

Topics & keywords

Topics
Keywords
  • Medicine
  • Cancer research
  • DYRK1A
  • Kinase
  • ROS1
  • Pharmacology
  • Tyrosine kinase
  • Ruxolitinib
No related works found for this paper.